Health Canada has issued Class II Medical Device Licenses for Fujirebio’s Lumipulse G pTau217 Plasma and Lumipulse G NfL Blood assays, expanding access to two blood-based neurological biomarkers that answer fundamentally different clinical questions. The pTau217 assay is intended to help identify amyloid pathology associated with Alzheimer’s disease in symptomatic patients aged 50 and older in specialized-care settings, while the NfL assay quantitatively measures neurofilament light chain, a biomarker of neuro-axonal injury that can rise across multiple neurological diseases. Both assays run on Fujirebio’s automated LUMIPULSE G immunoassay platform and were already CE marked before the Canadian licensing decision.
The approvals reflect a broader shift in neurology toward blood-based biomarker testing. Alzheimer’s assessment historically relied heavily on clinical examination, cognitive testing, cerebrospinal-fluid biomarkers and amyloid PET imaging, while neurological injury across diseases such as multiple sclerosis and neurodegenerative disorders can be difficult to quantify using symptoms alone. Automated blood assays promise a less invasive and potentially more scalable source of biological information, although their role depends heavily on the specific biomarker and intended use.
What does Fujirebio’s pTau217 blood test detect?
The Lumipulse G pTau217 Plasma assay measures tau protein phosphorylated at threonine 217. pTau217 has emerged as one of the most specific blood-based biomarkers associated with Alzheimer’s disease pathology because concentrations rise in relation to amyloid and tau processes characteristic of the disease. Fujirebio’s Canadian indication is designed to help clinicians identify underlying amyloid pathology in people aged 50 or older who already show signs or symptoms of cognitive decline.
The assay is not intended to diagnose Alzheimer’s disease completely on its own. Fujirebio states that the result should be used as an adjunct to other diagnostic evaluations in specialized care, meaning physicians must still consider symptoms, medical history and additional investigations. That distinction prevents a positive blood result from being interpreted as equivalent to a complete neurological diagnosis.
How is the NfL blood test different from pTau217?
Neurofilament light chain is a structural protein found in neurons. When nerve cells or axons are damaged, NfL concentrations can rise in blood and cerebrospinal fluid, making it a broad marker of neuro-axonal injury rather than a biomarker specific to one disease. Fujirebio notes that NfL has been studied across multiple neurological conditions for potential use in prognosis, disease monitoring and assessment of treatment response.
That means the two newly licensed tests are complementary rather than interchangeable. pTau217 asks whether a patient’s biology is consistent with Alzheimer’s-associated amyloid pathology, while NfL provides information about the presence or intensity of neuronal injury more broadly. A patient could therefore have elevated NfL for reasons unrelated to Alzheimer’s disease, which is why age-adjusted reference values and clinical context are central to interpretation.
Why are blood-based Alzheimer’s biomarkers gaining momentum now?
The emergence of disease-modifying Alzheimer’s therapies has increased the importance of confirming underlying pathology. When treatment targets amyloid, physicians need to know whether amyloid pathology is actually present before exposing a patient to medication, monitoring burden and potential adverse effects. Blood testing can potentially make that initial biological assessment easier than relying immediately on PET imaging or lumbar puncture.
Fujirebio is not alone in moving pTau217 into automated clinical diagnostics, which is a sign that the field is progressing from academic biomarker research toward competing commercial platforms. The important competitive factors are likely to include analytical performance, clinical cutoffs, throughput, installed analyzer base, reimbursement and how easily laboratories can integrate the tests into existing workflows.
What does automation change for neurology laboratories?
A biomarker can be scientifically strong yet difficult to use routinely if testing requires specialized research equipment or manual laboratory processes. Fujirebio’s assays run on the LUMIPULSE G platform, allowing laboratories equipped with the system to process samples through a standardized automated immunoassay workflow. This can potentially improve reproducibility and turnaround time while lowering the practical barrier between neurological research and everyday diagnostic use.
Automation also matters as test volumes rise. If blood biomarkers become part of broader dementia workups, laboratories may eventually process far more pTau tests than the number of amyloid PET scans currently performed. The commercial opportunity therefore depends not only on biomarker accuracy but on whether laboratory infrastructure can scale to support routine demand.
Could pTau217 eventually reduce the need for PET scans and lumbar punctures?
For selected patients, that is a central ambition of blood-based Alzheimer’s testing, but a blood test will not automatically eliminate confirmatory investigations. Clinical pathways may use blood biomarkers first to identify patients with a high or low probability of amyloid pathology and then reserve PET imaging or cerebrospinal-fluid analysis for uncertain or treatment-critical cases. This type of triage could reduce cost and improve access, particularly in regions where advanced neurological imaging is concentrated in major centers.
The exact role of Fujirebio’s assay in Canada will depend on clinical guidelines, reimbursement and how specialists incorporate the result into treatment decisions. Its approved indication as an adjunct reflects that evolving landscape rather than declaring pTau217 a complete replacement for existing diagnostic methods.
Why could the NfL assay have applications beyond Alzheimer’s disease?
Because NfL reflects neuronal injury rather than one specific pathology, it has been studied across multiple sclerosis, traumatic neurological injury and several neurodegenerative disorders. Rising or falling NfL concentrations can potentially provide an objective biological measure alongside clinical symptoms and imaging. That makes it interesting for both routine neurology and pharmaceutical trials where developers want to know whether a treatment is changing underlying neuronal damage.
Fujirebio’s Canadian license does not mean NfL has one universal disease cutoff or that the assay can diagnose every neurological disorder. The company specifically emphasizes clinical context and age-adjusted reference values, which is important because NfL naturally varies and can be affected by multiple conditions. The broader opportunity is to use one measurable biological signal across different clinical questions rather than forcing it into a single-disease interpretation.
What should the diagnostics industry watch next?
The pTau217 market is moving rapidly enough that competition may become as important as scientific validation. Laboratories and healthcare systems will increasingly compare automated assays according to accuracy, clinical performance, available regulatory indications and cost. Companies able to combine several neurological biomarkers on one analyzer may have an advantage because clinicians are unlikely to rely on one marker for every stage of neurological disease.
Fujirebio’s September 1 Canadian licenses therefore matter for more than two individual assays. They show how neurology diagnostics are shifting from specialized imaging and cerebrospinal fluid toward automated blood testing capable of answering increasingly specific biological questions. The next phase will determine whether these tests remain concentrated in specialist centers or become part of a much broader pathway for evaluating cognitive decline and neurological injury.
